MERS Fears Prompt Korean Ribavirin Plans
This article was originally published in PharmAsia News
Executive Summary
Amid mounting fears over massive spreading of Middle East Respiratory Syndrome (MERS) in South Korea, where the number of confirmed cases totals 35 so far, pharma firms are discussing with the government a possible increase in production of ribavirin, which is known to be partly effective against the virus.